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Abstract: Modifier genes are an integral part of the
genetic landscape in both humans and experimental
organisms, but have been less well explored in mammals
than other systems. A growing number of modifier genes
in mouse models of disease nonetheless illustrate the
potential for novel findings, while new technical advances
promise many more to come. Modifier genes in mouse
models include induced mutations and spontaneous or
wild-derived variations captured in inbred strains. Identi-
fication of modifiers among wild-derived variants in
particular should detect disease modifiers that have been
shaped by selection and might therefore be compatible
with high fitness and function. Here we review selected
examples and argue that modifier genes derived from
natural variation may provide a bias for nodes in genetic
networks that have greater intrinsic plasticity and whose
therapeutic manipulation may therefore be more resilient
to side effects than conventional targets.
A Brief Conceptual History of Modifier Genes
The concept of modifier genes originated with the solution to an
early genetic mystery. As early workers tested Mendel’s segrega-
tion ratios with observations on a wide range of traits and species,
several cases of ‘‘inconstant inheritance’’ caused some to question
the Mendelian basis of factors underlying these traits [1,2]. Three
cases of particular note are Beaded and truncate wings in fruit flies
and pigmentation in hooded rats. In each of these cases, the
phenotype varied widely among offspring of parents with
established genotypes. Mutant frequencies did not follow Mende-
lian ratios and—more troubling still—varied among derived lines
carrying the same mutation. This led some workers to question
whether genes were constant physical units or changed in
properties during transmission [3,4] and was the last serious
challenge to the theory of the gene and the generality of
Mendelian inheritance. Resolution of this issue came with
demonstrations that defined genetic backgrounds could account
for the variation in truncate flies [5] and hooded rats [6,7] and more
precisely, by linkage mapping, that discrete genetic loci account
for the observed variation in Beaded flies [8]. The term ‘‘modifier
gene’’ was coined to indicate a genetic variant identified by its
impact on a conditioning mutation, with no obvious phenotype of
its own. This is the usage we will follow here (Box 1).
Early workers quickly appreciated that modifier genes are
pervasive across experimental systems and organisms. Modifier
genes need not be subtle and can have phenotypic effects as large
as the initial conditioning mutation. These early observations
contributed to the conceptualization of genetic pathways, prior to
knowing the molecular identities of any components. This formal
concept remains useful in analyzing genetic networks for sensitive
nodes (genes) through which to manipulate mutant phenotypes in
genetic disease or experimental biology.
Modifier Genes in Human Disease and Mouse
Models: Ripe for Harvest
Modifier genes are also frequent in human disease and often
invoked to explain divergent outcomes in genetic disorders with
apparently equivalent cause. Among the best examples is cystic
fibrosis (CF). CF patients homozygous for the D508 allele
(approximately half of patients with European ancestry) present
with a broad range of organ involvement and clinical severity,
much of which is controlled by modifier genes [9]. Despite being
among the most common Mendelian disorders and having an
unusually common disease allele to minimize heterogeneity,
molecularly defined modifiers have only very recently been
reported [10,11]. Just as CF was one of the first major victories
in positional cloning of disease genes, its modifier gene network is
one of the first to see real progress apart from candidate genes and
serendipitous studies. Comparison between modifier studies in
human patients and mouse models of CF [12–15] will be especially
interesting, given replication of at least one syntenic locus between
species [16]. Among rarer disorders, some ciliopathy phenotypes
(and related developmental abnormalities) may require or be
modified by tri-allelic inheritance—requiring three alleles among
two or more loci—among functionally related genes [17–21].
However, these examples are the exceptions. Most modifier effects
in human genetic disorders are much less well understood, and the
numbers of available subjects, allelic heterogeneity, and environ-
mental factors that obscure modifier effects in smaller cohorts may
limit systematic analyses for a large number of individually rare
disorders. This increases the potential value of animal models for
both candidate discovery and experimental validation of human
modifier genes.
Identification of modifier genes in mouse models offers an
opportunity to understand forms of plasticity in mammalian
genetic architectures that could be exploited as a preclinical
knowledge base in designing therapeutic strategies [22]. A very
common finding in mouse models is phenotypic difference
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lines from gene-targeting experiments), but the sources of variation
are not often pursued because of technical and resource
constraints. Limited access to these modifier genes is a missed
opportunity. Since modifiers are necessarily context dependent,
any experimental organism is likely to model only a portion of any
particular genetic network in disease. The accuracy of multigenic
models likely depends on both the evolutionary plasticity of the
network involved and the evolutionary distance between the
model and human subjects. From this perspective, with rodents as
a sister group to primates, mouse variants that have large effect
sizes as modifiers while remaining phenotypically quiet on their
own should be useful in identifying points in a genetic network
where intervention might have higher therapeutic benefit than
collateral cost.
The examples below argue that modifier genes are a field ripe
for harvest, particularly with the recent arrival of several new
community resources that improve experimental access to genetic
variations among common strains. The situation is reminiscent of
early days of positional cloning in many respects. Large numbers
of loci have been reported and mapped (Figure 1; Table S1), but
few have been molecularly identified. Stories of unrewarded efforts
have inhibited some investigators from pursuing otherwise
tantalizing genetic effects. The two most important parallels,
however, are that early successes—highlighting unexpected
interactions—show the value of the approach and that new
resources and emerging technologies are making the approach
both more palatable and more cost effective. With new tools and a
critical mass of encouraging results from several laboratories, this
is a good time to consider both the value of the waiting crop and
the machinery needed for harvest. Instructive examples to date
include identification of genetic interactions from candidate genes,
from mutagenesis screens, and from natural variants. Understand-
ing modifier gene network architectures in mouse models may
provide a powerful functional basis for inferring candidate
interactions from human exome and genome sequences, partic-
ularly where sample size limits statistical power for independent
discovery in clinical samples for Mendelian disorders.
Candidate Genes Are a Useful, but Limited, View
of Interactions
Many of the genetic interactions known in mice come from
direct tests of candidate interactions. Testing interactions first
observed in other species can identify physiological context for
gene pairs or networks that are conserved more deeply than the
physiology or organ system for which they are most relevant to
human disease. For observed binding partners, genetic interactions
can test the biological relevance of likely physical contacts.
Proposed interactions between mutations with similar phenotypes
can also clarify points of convergence between previously separate
pathways.
Candidate interactions are often based on homology to
interacting genes in other species, including components of
developmental signaling pathways, homeotic regulators, and
transcription factor cascades in development. Some of these
interactions may confirm modifier genes in the strict sense of Box
1, but more often involve interactions between phenotypic null
mutations available from other studies. While these are helpful in
confirming functional conservation among pathways and defining
mammalian contexts that might be relevant to disease, this
paradigm is limited in its ability to identify levels of interaction
unique to mammalian biology that might be expected from
successive genome duplications, rescissions, and neo-functionaliza-
tion in the lineage leading from ancestral vertebrates to primates
and rodents (Euarchontoglires). Indeed, levels of redundancy
among paralogous genes in mouse experiments often underscore
important differences in trait architectures between mammals and
other models. Moreover, focus on just the highly conserved rather
than more plastic components of a genetic pathway or network
might bias against finding genes that are more readily manipulated
without damage to the organism.
Figure 1. PubMed references to mouse modifier genes. Growing
interest in and recognition of modifier genes in mouse models is
supported by increased publication rates in 5-year windows for the last
30 years. Mouse modifier papers have increased at a rate faster than the
increase of total PubMed citations over the past 15 years.
doi:10.1371/journal.pgen.1002644.g001
Box 1. What Is a Modifier Gene?
The term has been applied to several classes of genetic
activities, some of which overlap. Genetic variations that
alter the activity of a protein encoded by a second locus
are one class. To the extent that the modifying effect is
independent of allelic variation in the gene being
modified, this usage is conceptually equivalent to any
primary mutation whose phenotypic consequences in-
clude loss of interaction with its normal targets (as for a
transcription factor and its target genes, or a protein
kinase and its substrates). Interactions between mutations
that were each previously recognized by their indepen-
dent phenotypes are another class. While these genetic
interactions can be revelatory, one need not invoke the
term ‘‘modifier’’ to fully describe both individual and
interaction effects, as each locus is identifiable without the
other. Quantitative trait loci (QTL) are sometimes referred
to as modifiers in the context of a major effect locus, which
can be nearer the original meaning, depending on the
structure of interactions in the QTL model. For the
purposes of this review, we will use ‘‘modifier’’ to mean
a genetic variant that is best recognized by its ability to
change the phenotypic outcome of an independent
‘‘conditioning’’ variant at another locus. Modifier genes in
this usage have no obvious phenotype of their own prior
to discovery and are effectively silent—or at least quiet—
with respect to the phenotype under study, in the absence
of the conditioning mutation.
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alleles are another kind of candidate gene approach. For example,
BALB/c and 129S1 mice are sensitive to adriamycin-induced
nephropathy and show mitochondrial DNA (mtDNA) depletion in
vulnerable organs after adriamycin treatment. Gharavi and
colleagues identified a single amino acid substitution in the shared
BALB/c and 129S1 allele of Prkdc, which encodes a DNA-
activated protein kinase, as the sensitizing variant and asked
whether this might be relevant to other mtDNA dysfunctions [23].
The human orthologue of Mpv17, which encodes an inner
mitochondrial membrane protein, is mutated in mtDNA depletion
syndromes [24], but the corresponding mouse mutation does not
produce this phenotype. Papeta et al. showed that Prkdc potentiates
mtDNA loss in Mpv17-mutant mice: double mutant mice (but
neither single mutant) suffer mtDNA loss and other features of
adriamycin-induced nephropathy without adriamycin exposure,
providing parallel gene6gene and gene6environment models.
The many successes in modeling the phenotypic consequences
of predicted candidate gene interactions in an intact mammal
should encourage us to consider what value might be obtained
from screens that are less constrained by prior predictions—and
therefore capable of identifying novel and unexpected interactions
that might catalyze more rapid progress in the often complex
genetic architectures relevant to disease.
Spontaneous Modifiers: Volunteers Lead the Way
An early success in using modifier genes to understand a genetic
networkinmicecamefromthedilutesuppressor(Mreg
dsu).Thismodifier
arose spontaneously in a non-agouti, dilute stock, suppressing the coat
color dilution but with no obvious phenotype of its own [25].
Importantly, dsu similarly suppressed pigmentation phenotypes in
mutations at five of 11 classical coat color loci tested [26,27],
indicating a fundamental role in melanosome function. Molecular
analysis revealed a spontaneous 11-kb deletion, creating a null allele
in a vertebrate-specific gene, subsequently dubbed Melanoregulin [28].
Characterization of Melanoregulin in the context of its genetic
suppressor activity revealed a previously unknown molecular
function required for pigment granule transfer and other transac-
tions among membrane-bound organelles [29]. This work remains
an instructive example as few other strict-sense modifiers have been
demonstrated to act on several different mutations and only one
mouse modifier, Nxf1
Mvb1, has been effective on a larger number.
Spontaneous mutations can also contribute to nominally wild-
type inbred backgrounds. The Sodium channel modifier 1 (Scnm1) locus
was identified as a strain-dependent modifier of Scn8a
med-J,a
mutation in a neuronal sodium channel gene responsible for a
range of neurological phenotypes [30]. Among several Scn8a
mutations, the modifier is specific for the med
J allele, an intronic
single nucleotide variant that alters 59 splice site usage. Positional
cloning of the modifier identified a novel gene whose protein plays
a direct and previously unsuspected role in pre-mRNA splicing
[31,32]. The sensitizing modifier allele (C57BL/6) encodes a
truncated protein (R187X), but is less severe than a subsequently
generated null allele [33]. The interaction between Scnm1 and
Scn8a
med-J appears highly specific, as Scnm1 does not alter general
RNA patterns in brain nor modify other tested mutations with
similar defects [33]. Because the variant Scnm1 allele is only found
in C57 and C58 strains, but not in other strains with otherwise
similar Scnm1 haplotypes, it is proposed to have arisen as a
spontaneous mutation in a progenitor stock rather than as a wild
population variant [32]. The unexpected aspects of mammalian
biology identified through the dsu and Scnm1 spontaneous
modifiers should encourage further explorations of modifier genes.
Induced Mutations Allow Systematic Screens—
with Dramatic Effects
Random mutagenesis to introduce and screen new variants has
several advantages for identifying genetic interactions and trait
architectures. Ethylnitrosourea (ENU) is especially efficient in mice
[34,35] and in principle can both produce a range of alleles at a
given locus and saturate a phenotype for simple loss-of-function
alleles at most loci. High-throughput sequencing now rapidly
identifies de novo mutations relative to a defined background [36–
38]. With respect to modifier screens, mutagenesis should in
principle identify both strict-sense modifiers and interacting genes
with significant independent phenotypes, though the relative
proportion may be difficult to predict.
Using epigenetically sensitive Agouti alleles and green fluorescent
protein (GFP) transgenes that show variegated expression as
phenotype reporters, Whitelaw and coworkers have recovered a
substantial collection of ENU-induced Modifier of murine metastable
epialleles dominant (MommeD) mutations. This approach creates an
‘‘outside-in’’ interaction network module, with multiple edges
(interactions) converging on a single node (conditioning mutation
or reporter gene) (Figure 2A). At least five of these mutations have
been molecularly identified, encoding core components of
chromatin regulatory complexes and a DNA methyltransferase
[39–42]. The first recessive mutation identified from this screen,
MommeR1, is an amino acid replacement allele of transcription
factor Foxo3a [43]. Each of these mutations has independent
phenotypes in addition to the modifier activity, including recessive
lethality for the dominant alleles and female infertility for Foxo3a.
Another instructive example comes from an ENU screen for
dominant enhancers of dominant white spotting in a Sox10
lacZ/+
model of Waardenburg syndrome [44]. Among 230 pedigrees,
Pavan and colleagues recovered three transmissible modifiers of
spotting (Mos1,2,3). Remarkably, these three induced mutations
mapped to locations distinct from several previously identified
modifiers of Sox10 and from each other, suggesting that Sox10
phenotypes are sensitive to perturbations at many positions in an
extended genetic network. A collateral phenotype (cephalosyn-
dactyly) and map position strongly suggested Gli3 as the Mos1
gene, which sequence and complementation analysis rapidly
confirmed. Mos2 was subsequently identified as a null allele of
the RNA regulator Magoh, with severe haploinsufficiency pheno-
types in brain development [45].
As illustrated in these examples, chemical mutagenesis allows
efficient exploration of genetic networks unconstrained by prior
hypothesis. Networks ascertained by this approach, in both
examples, comprise modifier alleles that typically have indepen-
dent deleterious phenotypes. Whether this is more often true of
induced mutations or is a property of the specific networks tested,
and whether milder alleles at the same genes might retain modifier
effects without collateral phenotypes remains to be seen.
Alternatively, networks based on variants in natural popula-
tions—or nominally wild-type strains—might highlight different
genes and network connections, depending on biological trade-offs
between modifier effect and collateral phenotypes in any gene’s
potential allele spectrum and the forces of selection through which
a given variant has passed prior to discovery.
Natural Variants: Keys to Genetic Plasticity?
While inbred mouse strains are often referred to as nominally
‘‘wild type,’’ each represents a different sampling of wild (and a few
laboratory-derived) alleles across the genome. Inbred strains in
aggregate represent an abundant source of captive variation
PLoS Genetics | www.plosgenetics.org 3 April 2012 | Volume 8 | Issue 4 | e1002644[46,47] and the vast majority of underlying genetic variants
predate laboratory domestication [48–50]. This argues that the
captive variants—on average—were sufficiently neutral to be
sufficiently frequent among wild mice to be incorporated in the
common laboratory strains, although some specific instances will
be maladaptive by themselves or in combination with other
variants. Modifier alleles among the nearly neutral majority of
strain variants might be expected to favor, in comparison to
mutagenesis experiments, either milder alleles or nodes in the
relevant genetic networks with greater intrinsic plasticity—
functional variation compatible with normal phenotype. Identifi-
cation of network nodes with greater genetic plasticity may be
especially useful for pointing out experimental and therapeutic
approaches with higher likelihood to minimize collateral damage
in modifying a specific condition. Three examples of early
successes indicate some of the areas to which natural variants
might contribute unique findings.
Studies in several laboratories have identified modifiers that
alter Apc
Min-dependent tumor phenotypes in a genetic cancer
model [51–58]. Modifier of Min-1 (Mom1) is the most well studied,
beginning with its discovery by linkage analysis for intestinal tumor
number nearly two decades ago [57]. Based on rough map
location and strain distribution, the secreted phospholipase Pla2g2a
was proposed as a positional and functionally variant candidate
gene, with an apparent null allele caused by a single base insertion
in Apc
Min sensitive strains [59]. Mom1 is semidominant and analysis
of tumor DNA suggested that its effects are not cell autonomous,
consistent with its identification as a secreted enzyme. Comple-
mentation studies confirmed that Pla2g2a accounted for a large
fraction of the variance in tumor number [60] (an additional
component, Mom6, was inferred to account for the full effect of the
initial linkage [56], adding as a grace note that linkage peaks may
be driven both by variants of large effect and by regions containing
more than one contributing variant). Elevated expression of
human PLA2G2A was subsequently associated with survival in
gastric cancer patients [61], providing another example of cross-
species validation. Mom1 alleles in mice are widely distributed
across inbred strains, suggesting an early origin. Re-sequencing
[49,62] and dense genotyping [48] data provide a partial answer.
Review of published data shows that the Mom1 single base
insertion is a derived allele that arose on a unique haplotype and
that at least 2 Mb of this interval is shared by all characterized
Mom1
S-allele strains. (Surprisingly, C57BL/6 and wild-derived
MOLF/Ei strains share haplotype, 3630/3635 called variants,
across 2.4 Mb around Pla2g2a, suggesting contamination of the
MOLF/Ei stock with laboratory strains for this interval [63].)
While the origin of this Pla2g2a allele is not yet clear, the
circumstantial evidence warrants further investigation as a possible
wild variant.
The Heart failure modifier 2, one of several mapped Hrtfm loci that
modify the course of cardiomyopathy caused by overexpression of
calsequestrin [64], was recently identified as an allele of the
troponin-interacting kinase gene, Tnni3k, by a combination of fine
mapping, strain distribution, and transgenic studies [65]. Molec-
ular studies in a cell culture model implicated a single intronic
SNP as the functional variant, creating an alternate 59 splice donor
Figure 2. Modifier gene networks have directional edges between nodes. Mouse modifier gene interactions can be diagrammed as nascent
modules of an interaction network. (A) Identification of multiple modifier genes for a conditioning mutation through either mutagenesis or linkage
analysis of strain variants can be represented as in ‘‘outside-in’’ network module, where one node (the conditioning mutation, beige circle) is a sink
hub, acted on by each experimentally discovered modifier (light green circles). MommeD modifiers of the epigenetically sensitive A
vy mutation are
illustrated as an example. Direction of effect is indicated by the flared edges (connections) between nodes. (B) Validation of modifier mechanisms
across independent mutations result in an ‘‘inside-out’’ module, with the shared modifier (green circle) acting as a source hub on several conditioning
or test mutations. An incipient network around Nxf1
Mvb1, based on shared genetic mechanism, is illustrated. Atrn
mgL and several intronic ETn-induced
mutations are not affected by Nxf1
Mvb1 variation (gray). Pitpna
vb and Eya1
BOR have additional known modifiers (light green), adding modules to the
incipient network.
doi:10.1371/journal.pgen.1002644.g002
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transcripts in calsequestrin-resistant strains. To illustrate potential
origin of this strain variant, we tabulated both functionally tested
alleles [65] and correlated sequence data from additional strains
(Table 1) [62]. This shows a broad distribution of each allele across
accepted strain genealogies [66] for a region of modest haplotype
diversity, suggesting an origin prior to development of laboratory
strains and possibly wild-derived. Interestingly, subsequent work
implicates the same Tnni3k variant in susceptibility to coxsackie-
virus-induced myocarditis [67]. If this variant is confirmed as a
wild allele, it will be interesting to determine what factors might
account for its accumulation despite the increased risk to cardiac
challenges.
The Modifier of vibrator 1 was originally detected as a semi-
dominant modifier of neurodegeneration and premature death in
vibrator mutant animals. The Pitpna
vibrator mutation is an IAP-
family endogenous retrovirus insertion into an intron of a
phosphatidylinositol transfer protein gene, which reduces normal
gene expression by competing with splicing of the adjacent exons
[68]. Suppression by the CAST/Ei modifier allele occurs by
elevating the level and proportion of normally spliced mRNA
from the mutant gene. Positional complementation cloning
identified the modifier as an amino acid substitution allele of
mRNA nuclear export factor Nxf1, suggesting a previously
unexpected role for canonical mRNA export machinery in
splicing fidelity in at least some contexts [69]. Importantly, this
dose-responsive effect on alternative splicing has been demon-
strated for six out of seven mutations caused by sense-strand IAP
insertions in host gene introns, but none of 15 mutations with
other classes of insertional events [70]. This creates an ‘‘inside-
out’’ network module, with a modifier node acting on several
different mutations, some of which have additional known
modifiers (Figure 2B). Of special interest, the suppressing Nxf1
allele was found in a majority of wild castaneus isolates, confirming
it as a natural variant, and haplotype analysis suggested
directional selection, with a non-conservative amino acid
replacement in Nxf1 as the youngest variant on the most common
wild haplotype [69].
Among modifiers not yet identified molecularly, the Modifier of
dactylaplasia (Mdac) may impact several themes raised above,
including selection, specificity, and epigenetic regulation. The
functionally tested alleles are both well dispersed across inbred
strains [71,72], suggesting an early—and possibly wild—origin.
The modifier acts on two different Dac alleles of Fbxw4, caused by
independent insertions of MusD-family retrovirus elements at
different sites [73], but has no obvious independent phenotype in
reports from several different laboratories. Most interestingly,
Mdac alleles alter both DNA methylation and the accumulation of
inhibitory histone modifications on the Dac MusD elements [74],
raising the intriguing possibility that this locus might act directly in
epigenetic mechanisms, without strong collateral phenotypes. This
would be interesting both as a phenotypically quiet epigenetic
modifier and potentially as a tool for titrating allele strength of
other MusD/ETn-induced mutations with similar epigenetic
profiles.
Identifying modifiers on the basis of natural variants may
require more resources than de novo mutations (once generated),
but have the added value of generally highlighting alleles, genes, or
networks whose manipulation appears well tolerated by the
organism and largely compatible with normal function, having
been vetted by selective pressures. In the ultimate goal of finding
pressure points through which to modulate disease networks, this
may prove advantageous.
Going Forward: Tools for Accessing Strain
Variation and Modifier Genes
How readily can we use modifier genes to predict sensitive
pathways and nodes for therapeutic interventions? New tools and
resources in mouse genetics should help to unclog the pipeline of
modifier genes that have been detected but not molecularly
defined. Maps of copy number variation [75] and comprehensive
genome sequences of the most commonly used strains [62,76] will
be enormously powerful. The combination of predictive sequence
variants plus expression data from increasingly facile array and
RNA-Seq methods should allow comprehensive consideration of
candidate variants across even broadly defined loci. Because
modifier genes require the presence of the conditioning mutation,
strain resources built for genome-wide shuffling of alleles [77]
may have less value for this application (in requiring many crosses
to access the variation), while others such as chromosome
substitution panels [78,79] may be useful for isolating individual
modifier effects by limiting the need for de novo congenic strain
construction. New tools for functional validation at fine scale are
also essential to opening the pipeline of modifier gene studies in
mice. Recent developments on this front include an increased
diversity of strain-specific large-insert BAC libraries (http://
bacpac.chori.org/, among others) for transgenic studies, larger-
scale tools for engineering ES cells [80–82], and most recently
germline-potent ES cells from previously refractory strains [83].
These resources, some anticipated a decade ago [84,85] and
some less expected, are only now widely available. This
combination of tools and continuing innovations promises deeper
insight into mammalian genetic architectures in health and
disease, through the lens of modifier genes and mouse genetic
diversity.
Table 1. TNNI3 interacting kinase–Heart failure modifier 2 (Tnni3k
Hrtfm2) variant is widely distributed in laboratory mice.
Variant Granby Farm-Derived
a Swiss Mice
China and Japan
Stocks Other Inbred Wild Derived
Casq1-resistant variant (derived) and
haplotype
A/J, BALB/c,
C3H, DBA, NZO
NOD, NZO
Share haplotype, variant not tested I/Ln, MA/My, SEA DDK, KK BUB, RIIIS
Share haplotype w/o resistant variant WSB (North America)
Casq1-sensitive variant (ancestral) 129P2, 129S1, AKR,
C57BL/6, CBA
FVB CAST (Asia), PWK
(Europe)
aStrain categories are taken from [66]; Granby Farm-derived mice include both strains descended from Castle’s mice and C57-related strains, both of which derived in
part from A. Lathrop’s stocks at Granby Farm. Strain-specific sequences from [62]. Inferred haplotypes from [48].
doi:10.1371/journal.pgen.1002644.t001
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Table S1 A curated list of mouse modifier genes. The attached
spreadsheet collects several examples of modifiers and a few
exemplar interactions that may strain the strict definition of the
term. Entries were manually curated from entries in the Mouse
Genome Database [86,87] with modifier, suppressor, or enhancer
annotations; independent nested searches of PubMed for similar
terms; authors’ recollections; referrals from colleagues and
suggestions from anonymous reviewers. We acknowledge that
the list is incomplete and apologize to colleagues whose work we
have missed by this limited search strategy. We have not
independently reviewed the strength of linkage evidence for
named loci. Molecularly identified modifier genes are emphasized
with red text.
(XLSX)
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